Indicator Explainer
Interleukin-23
A heterodimeric cytokine composed of interleukin-12 subunit beta and interleukin-23 subunit alpha. This complex binds to the interleukin-23 receptor complex, which activates the JAK-STAT signaling pathway and modulates the proliferation, differentiation and effector functions of T-lymphocytes, natural killer cells and some myeloid lineage cells.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C147535. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — Interleukin-23 (C147535)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C147535. NCI definition, reproduced without modification under CC BY 4.0.
- Real-world adherence to biologic therapies targeting interleukin 17, interleukin 23 and ustekinumab in moderate-to-severe psoriasis: A multicenter cohort study. — Farm Hosp, 2026-10-14 (PMID 42875349; literature)
- EBV-positive Hodgkin lymphoma with an immunosuppressive microenvironment during guselkumab (interleukin-23 inhibitor) therapy for chronic plaque psoriasis. — J Hematop, 2026-10-09 (PMID 42853462; literature)
- Clinical and scintigraphic improvement of mandibular involvement associated with chronic nonbacterial osteitis following an interleukin-23 inhibitor: a case-based literature review. — Immunol Med, 2026-09-25 (PMID 42788865; literature)
- Comparative drug survival and effectiveness of interleukin-17 inhibitors versus selective interleukin-23 inhibitors following discontinuation of ustekinumab in plaque psoriasis: A retrospective cohort study. — J Am Acad Dermatol, 2026-09-11 (PMID 42726047; literature)